ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Arbuck Leaves NCI to Guide BMS Oncology Pipeline.

September 7, 2001

Newell, Fredrickson Question Ethics Of Laetrile Trials

July 22, 1977

Two New Therapies For Metastatic Cancer Highlighted At AACR Annual Meeting

August 29, 2003

Obama Picks Daschle for HHS Secretary. Waxman Gains Chairmanship of Energy & Commerce.

November 21, 2008

CCOP Review Completed; 72 Applications Submitted, 23 More For Minority CCOP

December 1, 1989

NIH RFA Available

August 3, 2001